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Abstract  
Prostaglandin (PG) E2 plays an important role in the modulation of the immune response and 
the inflammatory process. In this study, we describe a PGE2 positive feedback for 
Cyclooxygenase (COX) -2 and microsomal PGE Synthase (mPGES) -1 expression in the 
macrophage cell line RAW 264.7. Our results show that PGE2 induces COX-2 and mPGES-1 
expression, an effect mimicked by dibutyryl-cAMP (dbcAMP) or Forskolin. Furthermore, 
cAMP signaling pathway cooperates with LPS in the induction of COX-2 and mPGES-1 
transcriptional activation. Analysis of the involvement of EP receptors showed that incubation 
with EP2 agonists up-regulated both COX-2 and mPGES-1 mRNA levels. Moreover, EP2 
receptor over expression enhanced the transcriptional activation of COX-2 and mPGES-1 
promoters, being this induction abolished by the PKA inhibitor, H89. Activation of 
PGE2/EP2/PKA signaling pathway induced the phosphorylation of the cAMP response 
element-binding protein (CREB) in macrophages and stimulated the specific binding of this 
transcription factor to COX-2 and mPGES-1 promoters. Deletion or mutation of potential 
CRE sites in both promoters diminished their transcriptional activity. In summary, our data 
demonstrate that activation of PKA/CREB signaling through the EP2 receptor by PGE2 plays 
a key role in the expression of COX-2 and mPGES-1 in activated macrophages. 
 
Key words: COX-2, mPGES-1, EP receptors, Lipid mediators, Inflammation, Gene 
Regulation. 
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INTRODUCTION 
Prostaglandins (PGs) and Thromboxanes (TXs) are important lipid mediators involved in 
physiological and pathological processes. These agents are generated from the conversion of 
arachidonic acid (AA) into the intermediate mediator PGH2 by two different 
cyclooxygenases, COX-1 and COX-2 (reviewed in [1, 2]). These enzymes are the target of 
non anti-inflammatory drugs (NSAIDs) [3]. COX-1 has been defined as a constitutive enzyme 
that generates PGs within physiological homeostasis. On the contrary, COX-2 is an inducible 
enzyme responsible for PG production in different pathologic processes involving 
inflammation such as infectious diseases, cancer, arthritis and atherosclerosis [4-7]. PGH2 is 
the substrate of different PG and TX synthases that, in turn, generate a range of prostanoids 
with potent and diverse biological effects, as PGD2, PGE2, PGF2α, PGI2, and TXA2. Three 
types of PGE synthases (PGES) participating in the synthesis of PGE2 have been described: 
one cytosolic (cPGES) and two membrane-associated PGE synthases (mPGES)-1 and -2 [3, 
8]. mPGES-1, which belongs to the Membrane-Associated Proteins involved in Eicosanoid 
and Glutathione metabolism (MAPEG) superfamily, is inducible by similar stimuli that 
induce COX-2, being its induction also suppressed by glucocorticoids. Moreover, mPGES-1 
appears functionally coupled with COX-2 and its induction is usually coordinated with COX-
2 [9]. In macrophages, large amounts of PGE2 are generated during the inflammatory process, 
due to up-regulation of both COX-2 and mPGES-1 enzymes. Coordinated induction of the 
expression of COX-2 and mPGES-1 has been reported upon pro-inflammatory stimuli as 
LPS, IL-1β or TNFα, in several cell types [10-13].  
Prostanoids released into the extracellular medium exert their biological effects in an 
autocrine or paracrine fashion upon interaction with prostanoid receptors present in target 
cells. PGE2 signals through four G protein coupled receptors named EP1, EP2, EP3 and EP4 
(reviewed in [14-17]). EP receptors are linked to different transduction pathway that may 
even give rise to opposite effects, activation or inhibition, on cellular responses. Thus, EP1 
induces inhibition of adenylate cyclase, leading to a decrease in cAMP, whereas EP2 and EP4 
receptors activate this enzyme. On the other hand, EP3 is coupled to Gαq and its activation 
results in intracellular calcium increase. 
cAMP is thought to be the main intracellular second messenger of PGE2 signaling in 
macrophages playing a crucial role in the modulation of the functional activity of 
macrophages and monocytes. In fact, PGE2 –dependent elevation of intracellular cAMP in 
LPS -stimulated macrophages results in a decreased synthesis of pro-inflammatory cytokines, 
including tumor necrosis factor (TNF) –α [18, 19], Interleukin (IL)-1β [20] and in an 
increased production of the inflammatory cytokine IL-10 [21]. On the other hand, stimuli 
known to elevate intracellular cAMP levels such as PGE2 may positively modulate COX-2 
expression [22, 23].  
We have previously reported an essential role of NF-κB and Egr-1 as key factors involved in 
coordinated up-regulation of COX-2 and mPGES-1 expression in macrophages in response to 
LPS, leading to increased PGE2 production [13]. In this study we explore the importance of 
cAMP signaling in the regulation of COX-2 and mPGES-1 in LPS –stimulated macrophages, 
analyzing the role of PGE2 -dependent signaling. Our data show that PGE2 induces 
transcriptional activation of both COX-2 and mPGES-1 via mechanisms involving EP2 
receptor activation and cAMP/PKA/CREB signaling pathway. This positive feedback 
regulation of PGE2-synthesizing enzymes COX-2 and mPGES-1 in macrophages constitutes 
an amplification signaling that may play an important role in the modulation of the 
inflammatory process and the immune response. 
 4 
EXPERIMENTAL PROCEDURES 
Cell culture and reagents 
The mouse macrophage cell line RAW 264.7 (American Type Culture Collection, Rockville, 
MD) was cultured in RPMI 1640 medium (Invitrogen) supplemented with 5% fetal calf serum 
(BioWhittaker-Lonza), 100 U/ml penicillin, 100 µg/ml streptomycin, 1000 U/ml gentamycin, 
2 mM L-glutamine and 0.1 mM non-essential amino acids. Cells were treated with LPS from 
E. coli, serotype 026:B6 (Sigma-Aldrich), at 1 μg/ml. Selective COX-2 inhibitors Celecoxib 
and NS398 (Alexis Biochemicals) were used at final concentrations between 0.01 and 1 µM. 
PGE2, EP2 and EP4 agonists CAY10399 and PGE1OH, and EP2 antagonist AH6809, were 
purchased to Cayman BioChemical. dbcAMP (100 µM) (Sigma) and Forskolin (10 µM) 
(Biomol International) PKA inhibitors H89 (10 µM) and KT5720 (1 µM). Inhibitors were 
added 1 hour before cell stimulation with PGE2 or LPS. 
Plasmid constructs 
COX-2 promoter luciferase constructs PGHS-2 medium (-1844) was provided by Dr. S. 
Vogel (University of Maryland, Baltimore, MD, USA) [24]. PGHS-2-400 PGHS-2-250 
constructs were kindly provided by Dr. H. Herschman (University of California at Los 
Angeles, Los Angeles, CA, USA) [25]; PGHS-2-150, PGHS-2-88 and CRE-mutated PGHS-
2-400 and PGHS-2-88 constructs were generated by Dr. Virginia Vila-del Sol [26]. Luciferase 
constructs containing different deletions of the murine promoter of mPGES-1: mPGES-1-895, 
mPGES-1-694, mPGES-1-483 and mPGES-1-154 have been previously described [13]. The 
cAMP responsive element (CRE)-LUC plasmid contains four copies of the CRE site of the 
human choriogonadotropin gene promoter (−147 to −129)  [27]. EP2 expression vector 
(pcDNA 3.1-EP2) were obtained from Missouri S&T UMR cDNA Resource Center. The 
expression vector for the catalytic subunit of PKA has been previously described [28]. 
Transient transfection 
COX-2 and mPGES-1 promoter activity was analyzed by luciferase reporter gene assays. 
RAW 264.7 cells were transiently transfected with 0.5 to 2 µg of the different luciferase 
constructs along with 250 ng of pcDNA3 or pcDNA 3.1-EP2 plasmids using Lipofectamine 
2000 reagent (Invitrogen). After 5 hours of transfection, cells were treated with different 
stimuli for additional 18 h. Then, cells were harvested and lysed, and luciferase activity was 
determined by using a luciferase assay kit (Promega) in a luminometer Monolight 2010 
(Analytical Luminescence Laboratory, San Diego, CA). Transfection experiments were 
performed in triplicate. Results are expressed as fold induction ± SD (observed experimental 
RLU/basal RLU in absence of any stimulus). 
mRNA Analysis  
Total RNA was obtained from cells by the TRIzol reagent RNA protocol (Invitrogen). For 
standard RT-PCR, RNA (1 µg) was reverse transcribed by the RNA PCR core kit (Perkin-
Elmer). cDNA was used for PCR amplification to analyze EPs expression by standard RT-
PCR using specific primers for EP1: sense 5’-TTAACCTGAGCCTAGCGGATG-3’ and anti-
sense 5’-CGCTGAGCGTATTGCACACTA-3’; EP2: sense 5’-
CCACGATGCTCTCCTGCTGCTTAT-3’ and anti-sense 5’-
CAGCCCCTTACACTTCTCCAATGA-3’; EP3: sense 5’-TGAC CTTTGCCTGCAACCTG-
3’ and anti-sense 5’-GACCCAGGGAAACAGGTACT-3’; EP4, sense 5’-
CTTACTCATCGCCACCTCTCTGGT-3’ and anti-sense 5’-
TGTGGCTCCCACTAACCTCATCCAC-3’; and β-actin, sense 5´-
CTCTTTGATGTCACGCACGATTTC-3´and antisense 5´-
GTGGGCCGCTCTAGGCACCAA-3´. PCR reaction was amplified by 25 to 30 cycles of 
denaturation at 94 °C for 45 s, annealing at 55 or 60 °C for 45 s, and extension at 72 °C for 45 
s. PCR products were separated on agarose gel electrophoresis and visualized by ethidium 
bromide staining. Data shown correspond to a number of cycles where the amount of 
amplified product is proportional to the abundance of starting material. 
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For quantitative real-time RT-PCR analysis, total RNA was reversed transcribed using the 
components of the High Capacity cDNA Archive Kit (Applied Biosystems). Amplification of 
the COX-2 and mPGES-1 cDNAs was performed using the TaqMan Universal PCR Master 
Mix (Applied Biosystems) on an ABI PRISM 7900HT instrument (Applied Biosystems) for 
40 cycles with specific primers and Taqman MGB probes for COX-1, COX-2, mPGES-1, 
EP1, EP2, EP3, EP4 and 18S rRNA (Applied Biosystems). All samples were run in triplicate. 
Quantification of gene expression by real-time RT-PCR was calculated by the comparative 
threshold cycle (ΔΔCT) method following the manufacturer's instructions. Relative 
quantification (RQ) of mRNA levels was determined using endogenous expression of rRNA 
18S and is shown in all the experiments as RQ ± SD.  
Western blotting 
Protein extracts were obtained as previously described [13]. Protein concentration was 
determined by the BCA method (Thermo Scientific). Cell lysates were subjected to Western 
blot analysis using conventional SDS-PAGE gel electrophoresis and protein transfer to 
nitrocellulose filters. Membranes were incubated with the indicated antibodies and developed 
by the enhanced chemiluminescence system (Thermo Scientific). COX-2 and mPGES-1 
protein expression was detected using a monoclonal anti-COX-2 antibody (BD Transduction 
Laboratories) and a polyclonal rabbit anti-mPGES-1 antibody (Cayman Chemical). 
Antibodies against CREB and P-CREB were purchased from Upstate Signaling. β-Actin level 
was used as a control of loading in each lane. 
Chromatin Immunoprecipitation (ChIP) assay 
Specific binding of CREB and P-CREB to COX-2 and mPGES-1 promoters was determined 
by Chromatin immunoprecipitation assay (ChIP) assays as previously described [13]. Briefly, 
RAW 264.7 cells treated with PGE2 (5 µM) at indicated times were fixed with 1% 
formaldehyde and lysed in ice-cold lysis buffer (10 mM HEPES, 1.5 mM MgCl2, 10 mM 
KCl, 0.5 mM DTT, 0.1% NP-40 with protease inhibitors). Nuclei pellet was suspended in 
nuclear lysis buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS and protease inhibitors) 
and then chromatin DNA was sheared by sonication. Lysates were precleared with salmon-
sperm/protein A agarose. A sample of input DNA was collected. Protein-DNA complexes 
were immunoprecipitated overnight at 4°C with CREB or phospho-CREB polyclonal 
antibodies or non-immune rabbit serum as a control. Antibody-protein-DNA complexes were 
incubated with salmon sperm DNA/protein A-agarose for 30 min followed by washes with 
wash buffer (20 mM Tris-HCl pH 8, 2 mM EDTA, 0.1% SDS, 1% NP-40, 500 mM NaCl) 
and TE buffer (20 mM Tris-HCl, 2 mM EDTA). Protein/DNA complexes were eluted and 
disrupted by incubating at 65°C followed by proteinase K treatment. DNA was extracted with 
a QIAQUICK PCR Purification kit (QIAGEN). PCR was conducted using promoter specific 
primers for COX-2 and mPGES-1 and amplified bands were analyzed by 2% agarose gel 
electrophoresis. 
PGE2 determination 
PGE2 levels were measured in culture supernatants of RAW 264.7 cells after different 
treatment by a competitive immunoassay PGE2 EIA kit following manufacturer’s instructions 
(Cayman Chemical) 
Statistics 
Results are expressed as mean ± standard deviation (SD) from at least three independent 
experiments performed by duplicate or triplicate. Data were analyzed by ANOVA followed 
by Tukey´s test and by Student´s paired t-test to compare different assay groups using 
OriginPro 7.5 software. p < 0.05 was considered statistically significant. 
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RESULTS 
Effect of the inhibition of PGE2 production on LPS-mediated induction of COX-2 and 
mPGES-1 expression. 
Expression of enzymes involved in PGE2 biosynthesis as COX-1, COX-2 and mPGES-1 were 
assessed by quantitative real time RT-PCR in the murine macrophage cell line RAW 264.7 
after LPS treatment (Fig. 1A). Low levels of expression of COX-1 (average Ct = 33,11), 
COX-2 (average Ct =29,28) and mPGES-1 (average Ct= 32,15) were observed in these cells 
in basal conditions. Upon LPS treatment for 24 h., COX-2 and mPGES-1 mRNA levels were 
up-regulated by 20 and 5 fold respectively whereas COX-1 expression was reduced by 2 fold, 
thus pointing to COX-2 and mPGES-1 as the main enzymes involved in enhanced PGE2 
production in LPS treated RAW264.7 cells. Accordingly, treatment with increasing doses (1 
to 100 nM) of COX-2 inhibitors Celecoxib or NS398, led to a decrease in the production of 
PGE2 induced by LPS (Fig. 1B). 
In order to study the effect of COX-2 inhibitors on the expression of COX-2 and mPGES-1, 
mRNA levels were determined by quantitative real time RT-PCR in RAW 264.7 cells treated 
with LPS for 24 hours in the presence of increasing doses of NS398 or Celecoxib. As shown 
in Figures 1C,D,E and F, LPS -mediated increase of COX-2 and mPGES-1 expression was 
attenuated by increasing doses of NS398 and Celecoxib (1 to 100 nM) , suggesting that 
suppression of endogenous PGE2 may cause a reduction in LPS-induced expression of 
mPGES-1 and COX-2 mRNA. Moreover, attenuation of mPGES-1 and COX-2 expression by 
NSAIDs was effectively restored by exogenous PGE2 (Fig 1C,D,E and F). 
Induction of COX-2 and mPGES-1 expression by PGE2 
In order to analyze the effect of PGE2 on COX-2 and mPGES-1 expression, we treated 
murine macrophages RAW 264.7 with increasing doses of PGE2 (0.1 to 10 µM) for 24 h. 
Quantitative RT-PCR and Western blots showed that COX-2 and mPGES-1 expression was 
significantly enhanced in a dose-dependent manner by PGE2 (Figs. 2A and 2B). PGE2 
treatment led to an early induction of COX-2 mRNA whereas mPGES-1 mRNA reached peak 
levels at 24 hr after stimulation (Fig. 2C). Furthermore, PGE2 cooperated with LPS in the 
induction of COX-2 and mPGES-1 mRNA levels (Fig. 2D). 
EP2 participates in PGE2-dependent transcriptional induction of COX-2 and mPGES-1.  
Four different EP receptors mediate PGE2-dependent intracellular signaling [14-16]. In basal 
conditions, murine macrophage cell lines cells express mainly EP2 and EP4 receptors [29-31]. 
Analysis of mRNA levels for the EP receptors in control RAW264.7 cells confirmed the 
presence of EP2 and EP4 transcripts with very low levels of EP1 and EP3 ones (Fig 3A, left 
panel). Quantitative RT-PCR analysis showed Ct values above 38 for EP1 (38.15 ± 0.43) and 
EP3  (38.73 ± 0.01) receptors thus indicating low to negligible levels of expression. Ct values 
for basal expression of EP2 (35.56 ± 0.12) and EP4 (30.53 ± 0.03) receptors were in the low 
to moderate range. Upon stimulation with either PGE2 or LPS, EP2 mRNA levels increased 
in a time-dependent manner. On the other hand, both PGE2 and LPS treatment promoted a 
decrease in EP4 mRNA levels (Fig. 3A).  
Treatment of RAW 264.7 cells with the EP2 agonist, CAY10399 or with the EP4 agonist 
PGE1OH revealed that EP2 triggering participate in the induction of both COX-2 and 
mPGES-1 mRNA levels (Fig. 3B). Involvement of EP2 signaling in the induction of the 
expression of these enzymes was confirmed with the use of the EP2 antagonist AH6809, 
which was able to reverse PGE2-mediated effects (Fig. 3C). 
Moreover, luciferase assays using COX-2 and mPGES-1 mouse promoter constructs (PGHS-
2 Medium and pmPGES-1:-895) showed that transient expression of EP2 receptor mediated 
transcriptional activation of COX-2 and mPGES-1 after PGE2
PGE
 stimulation of RAW 264.7 
cells (Fig. 3D). 
dbcAMP increases COX-2 and mPGES-1 expression  
2 signaling through the EP2 receptor promoted an increase in intracellular levels of 
cAMP due to activation of adenylate cyclase [15]. Incubation of RAW 264.7 cells with the 
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cell permeable-cAMP analogue dbcAMP induced an early accumulation of COX-2 mRNA at 
3 and 8 h., whereas a significant increase in mPGES-1 mRNA levels was detected after 24 h 
of treatment (Fig. 4A). Analysis of protein levels by Western Blot showed an increase of 
COX-2 and mPGES-1 protein levels after dbcAMP treatment with maximal induction at 24 h 
(Fig. 4B). Coordinated increase in COX-2 and mPGES-1 expression after dbcAMP 
stimulation led to enhanced production of PGE2 by these cells (Fig. 4C).  
dbcAMP cooperates with LPS in the induction of COX-2 and mPGES-1  
Combined treatment of RAW 264.7 cells with LPS and dbcAMP strongly enhanced 
transcription of COX-2 and mPGES-1 genes. Induction of COX-2 and mPGES mRNA levels 
in these cells by LPS was enhanced in the presence of dbcAMP (Fig 5A), resulting in 
augmented PGE2 production by these cells (Fig 5B). The effect of dbcAMP on LPS-mediated 
transcriptional activation was also analyzed on COX-2 and mPGES-1 promoter activity. As 
shown in figure 5C, LPS and dbcAMP cooperated in the induction of the transcriptional 
activity of both promoters compared to the induction after stimulation with either dbcAMP or 
LPS. 
PKA regulates COX-2 and mPGES-1 expression by PGE2.  
Signaling through the cAMP pathway leads to the activation of PKA, that in turns may 
activate cAMP –dependent gene transcription [32, 33]. We next analyze the involvement of 
this signaling pathway in the activation of COX-2 and mPGES-1 expression in RAW 264.7 
macrophages. As shown in figure 6A, inhibition of PKA by H89, produced a decrease in the 
induction of COX-2 and mPGES-1 promoted by PGE2 treatment or by activation of the 
adenylate cyclase by Forskolin. PKA inhibition was also able to abolish EP2-mediated 
induction of COX-2 and mPGES-1 promoter activity after PGE2 treatment (Fig. 6B). 
Interestingly, overexpression of an expression vector for the catalytic subunit of PKA 
significantly increased activity of COX-2 and mPGES-1 promoters and cooperated with LPS 
to further induce transcriptional activation of these promoters (Fig. 6C). Moreover, inhibition 
of PKA by either H89 or KT5720 promoted a substantial reduction in LPS + dbcAMP 
induction of PGE2 production by RAW 264.7 cells (Fig. 6D). 
PGE2 induces CRE –mediated COX-2 and mPGES-1 expression  
Since CREB is the main transcriptional mediator of cAMP/PKA signal [32, 33], we evaluated 
the effect PGE2 on CREB phosphorylation and CRE –mediated transcriptional activation. 
Incubation of RAW 264.7 cells with PGE2 led to efficient CREB phosphorylation (Fig. 7A). 
Furthermore, PGE2 as well as Forskolin and dbcAMP activated CRE-dependent gene 
transcription of a luciferase reporter construct (Fig. 7B). CRE-dependent transcription upon 
PGE2 stimulation was enhanced in cells co-transfected with an EP2 expression vector (Fig. 
7C).  
Previous studies have described a functional CRE binding site in the murine COX-2 promoter 
[34]. We have analyzed the functional significance of this CRE binding site in PGE2-
depended COX-2 transcriptional activity by using different deletions of the COX-2 promoter 
in cells co-transfected with the EP2 receptor. Mutation of the sequence containing the CRE 
site within the COX-2 gene abolished the induction of COX-2 promoter activity by PGE2 in 
RAW 264.7 cells (Fig. 8A). Analysis of the activity of different deletions of the murine 
mPGES-1 promoter (mPGES-1-895, mPGES-1-694, mPGES-1-483, and mPGES-1-154) 
showed that deletion of the region located between the position –483/-154 of the mPGES-1 
transcription start site resulted in a clear reduction of the inducibility by PGE2 (Fig. 8C). 
Sequence analysis of this region in the mPGES-1 murine gene to identify potential CRE 
elements with the TRANSFAC Database and P-Match software [35] revealed the presence of 
two putative CRE elements (5´-tcagTGATAtgc-3´ and 5´-gtccTGAGCcaa-3´) located at the 
positions –301/-290 and -217/-206 of the mPGES-1 transcription start site, with a high score 
of core similarity (0.976 and 0.988) and matrix similarity (0.916 and 0.894). The capital 
letters indicate the positions in the sequence which match with the core sequence of the 
matrix, while the lower cases refer to the remaining position of a matrix.  
 8 
To confirm the involvement of CREB in the induction of COX-2 and mPGES-1 by PGE2, we 
examined CREB binding to mouse COX-2 and mPGES-1 promoters by ChIP assays in PGE2-
treated RAW 264.7 cells. As shown in figure 8B and 8D, PGE2 stimulation resulted in 
increased binding of CREB to both COX-2 and mPGES-1 promoters.  
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DISCUSSION 
PGE2 plays an important role in the modulation of the inflammatory and immune response 
through autocrine and paracrine signaling participating in the regulation of cytokine 
production, leukocyte migration, proliferation and differentiation [36-38]. Activation of 
specific EP receptors by this prostaglandin has been shown to regulate the function of many 
cell types including macrophages, dendritic cells, T and B lymphocytes, leading to both pro- 
and anti-inflammatory effects. Emerging data reveal that regulatory effects of PGE2 in 
inflammation depend on receptor subtype, cell population, and context of activation. 
Although mostly implicated as a pro-inflammatory agent, PGE2 is also able to down-regulate 
the expression of inflammatory cytokines and chemokines from activated macrophages and 
dendritic cells [18-21, 39, 40]. Macrophages are the main source of PGE2 generated in 
settings of inflammation upon activation by stimulus such as LPS, TNFα or IL-1β. Enhanced 
release of PGE2 in response to these stimuli is due to coordinated up-regulation of COX-2 and 
mPGES-1 enzymes [41, 42]. The molecular mechanisms that regulate PGE2 synthesis by 
macrophages involved transcriptional and post-transcriptional processes with NF-κB, CREB 
AP-1 and c/EBP transcription factors as critical modulators of COX-2 gene transcription [23, 
26, 34, 43]. On the other hand, induced expression of mPGES-1 depends essentially on Egr-1 
transcription factor, although other factors as NF-κB and SP1 have been also shown to 
participate in its regulation [13, 41, 44-46]. In this study we provide evidence that PGE2 is 
able to enhance transcriptional activation of COX-2 and mPGES-1 in LPS -activated RAW 
264.7 murine macrophage cell line. This PGE2 -mediated positive loop involves the activation 
of EP2/cAMP/PKA signaling pathway resulting in CREB –dependent transcriptional 
activation of COX-2 and mPGES genes.  
LPS treatment of RAW 264.7 cells induces the synthesis of COX-2 and mPGES-1 that is 
accompanied by a significant increase in the release of PGE2. Our results show that COX-2 
selective inhibitors down-regulate the expression of these enzymes at a concentration doses 
that abrogated LPS-mediated PGE2 production in RAW 264.7 cells, suggesting a positive 
regulation of this prostaglandin on the expression of COX-2 and mPGES-1. In fact, 
exogenous PGE2 treatment reversed the effect of COX-2 inhibitors in LPS stimulated 
RAW.264.7 cells. Moreover, PGE2 treatment in unstimulated RAW 264.7 cells was able to 
induce COX-2 and mPGES-1 transcriptional induction. The ability of PGE2 to promote COX-
2 and mPGES-1 expression in unstimulated cells was weak compared to LPS, but PGE2
PGE
 was 
able to enhance LPS –mediated up-regulation of both enzymes. Induction of COX-2 and 
mPGES-1 showed different kinetics, with a delay in mPGES-1 induction in comparison to 
COX-2. Although COX-2 and mPGES expression vary similarly in response to a variety of 
stimuli (IL-1β, LPS, TNFα, etc), there are multiple reports showing differences in the specific 
timing for induction, in such a way that induction of mPGES-1 is generally delayed with 
respect to COX-2 in several cell systems {Diaz-Munoz, 2010 #365; Stichtenoth, 2001 #161; 
Thoren, 2000 #162; Inada, 2006 #193; Kojima, 2002 #447; Han, 2002 #448}. These 
observations suggest a differential regulation of these enzymes in terms of the up-regulation 
and maintenance of steady-state expression levels. It has been reported some differences 
between these two genes that could be relevant to explain divergences in the timing of 
response to the same stimuli. The promoter of the human mPGES-1 gene lacks a TATA box 
unlike the COX-2 gene promoter. Furthermore, mPGES-1 mRNA does not contain AUUUA 
instability motifs that are present in the COX-2 mRNA {Forsberg, 2000 #195}. The delayed 
induction of mPGES mRNA with respect to COX-2 upon a stimulatory treatment thus can be 
explained on the basis of a smaller increase in the rate of gene transcription in the setting of a 
relatively stable mRNA. 
2 exert its effects through a family of G-protein coupled receptors named EP-1, -2, -3 and 
-4 that differ in their signal transduction pathways. EP2 and EP4 receptors are coupled to the 
Gs protein and activate adenylate cyclase, increasing cAMP levels [14-16]. In agreement with 
previous reports analyzing the expression of EP receptors in murine macrophages, we have 
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detected the expression of EP2 and EP4 in RAW 264.7 cells with negligible levels of EP1 and 
EP3 receptors [29, 30, 47-49]. Our results show that expression levels of EP2 and EP4 
receptors change inversely in such a manner that basal low levels of EP2 receptor are 
increased in a time dependent manner upon LPS treatment while EP4 expression diminished 
in stimulated RAW 264.7 cells. Moreover, a similar profile on the regulation of EP2 and EP4 
mRNA levels was observed upon PGE2 treatment. Differential regulation of EP2 and EP4 
receptors upon activation or PGE2 treatment involving cAMP signaling have been observed 
in murine macrophages [30, 47-49]. In the present study we provide evidences indicating the 
involvement of EP2 receptor in the PGE2 positive loop by the use of EP2 receptor agonists 
and antagonists as well as overexpression of this receptor in RAW 264.7 cells. EP2 receptor 
couples to Gαs leading to the activation of adenylyl cyclase and increased formation of 
intracellular cAMP and thus activation of the cAMP -dependent protein kinase PKA. Here we 
show that treatment of unstimulated RAW 264.7 cells with cAMP analogues or adenylate 
cyclase activators induced COX-2 and mPGES-1 expression resulting in augmented PGE2 
production. These agents cooperated with LPS to further up-regulate COX-2, mPGES-1 
expression and PGE2 production by RAW 264.7 cells. Involvement of PKA was revealed by 
the use of PKA inhibitors H89 and KT5720 which down-regulated cAMP –dependent 
transcriptional up-regulation of COX-2 and mPGES-1. Furthermore, overexpression of a 
catalytic active PKA was able to induce the activity of COX-2 and mPGES-1 promoters, both 
in basal and LPS-stimulated RAW 264.7 cells. Activation of PKA by cAMP can result in the 
phosphorylation of CREB that interacts with CREs, resulting in the regulation of cAMP 
responsive gene expression [32, 33]. Our study show that PGE2 treatment of RAW 264.7 cells 
induced phosphorylation of CREB at Ser-133, resulting in the transcriptional activation of a 
CRE-luciferase reporter. Induction of CREB mediated transcriptional activation of this 
reporter construct could be observed in the presence of overexpresed EP2 receptor. CREB –
dependent regulation of COX-2 promoter activity in response to a variety of stimuli have been 
observed in different cell types [34, 50-52]. Our Chip assays show that PGE2 treatment lead 
to CREB binding to the murine COX-2 promoter but also to the mPGES-1 promoter, 
involving for the first time this transcription factor in the regulation of this gene in response to 
cAMP -elevating agents. Moreover, analysis of the regulation of COX-2 as well as mPGES-1 
promoters activity by PGE2 in RAW 264.7 cells not only confirmed the role of the CRE 
sequence in the COX-2 promoter but localize a PGE2 responsive region (-483 to -154) within 
the murine mPGES-1 promoter containing two putative CRE elements.  
In summary, our results point to an essential role of the EP2 receptor in PGE2 -mediated 
regulation of COX-2 and mPGES-1 expression though the cAMP/PKA/CREB signaling in 
RAW 264.7 cells. An autocrine PGE2 positive feedback involving both EP2 as well as EP4 
receptors have been suggested previously as a mechanism modulating COX-2 induction and 
PGE2 production [51-54]. Our results cannot entirely discard the involvement of EP4 receptor 
–mediated signaling in these effects. EP2 and EP4 receptors apparently act redundantly in 
some processes although they show important functional differences that may explain their 
distinct roles in others [14, 15]. Even though these receptors share common signal 
transduction pathways through the activation of adenylate cyclase, they differ in their 
desensitization and internalization [55, 56] as well as in the signaling properties [15, 57]. Gs-
mediated increases in cAMP seem to play a less important role for EP4 receptor signaling 
compared with the EP2 receptor in such a way that inhibition of PKA by H89 is able to 
attenuate PGE2
In summary, our study demonstrates the existence of a positive feedback regulation of PGE
 mediated phosphorylation of CREB in EP2 expressing cells but not in EP4 
expressing cells [57]. Furthermore, the existence of a functional switch from EP4 to EP2 upon 
macrophage treatment with LPS or with cAMP elevating agents, in such a way that EP4 
receptor is down-regulated while EP2 expression levels are increased, points to EP2 as the 
predominant isoform in activated macrophages (this report and[47, 49]). 
2-
synthesizing enzymes as COX-2 but also mPGES-1 in macrophages, which may play an 
 11 
important role in the actions of this prostaglandin in the modulation of the inflammatory 
process and the immune response. 
 12 
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FIGURE LEGENDS 
 
Figure 1. Inhibition of PGE2 synthesis by COX-2 specific inhibitors reduces COX-2 and 
mPGES-1 gene expression in macrophages. A) RAW 264.7 cells were treated with LPS (1 
µg/ml) for 24 hours and COX-1, COX-2 and mPGES-1 mRNA levels were analyzed by real 
time quantitative RT-PCR, normalized to the expression of 18S rRNA. Results are shown as 
the mean of fold induction ± SD over the levels in the absence of LPS treatment. B) RAW 
264.7 cells were treated with LPS (1 µg/ml) for 24 hours in the presence or absence of 
increasing doses (1 - 100 nM) of COX-2 inhibitors NS398 or Celecoxib. PGE2 production in 
cell supernatants of RAW 264.7 cells was determined by a standard EIA assay as described 
under “Materials and Methods”. Analysis of COX-2 (C-D) and mPGES-1 (E-F) mRNA levels 
by real time quantitative RT-PCR in RAW 264.7 cells treated with LPS for 24 hours along 
with increasing doses (1 to 100 nM) of Celecoxib (C-E) or NS398 (D-F) in the presence or 
absence of PGE2 (5 µM) as indicated. COX-2 and mPGES-1 mRNA levels were normalized 
to the expression of 18S rRNA and are shown as % of induction ± SD considering 100 % the 
induction obtained upon LPS treatment. (*p<0.05; **p<0.01). 
 
Figure 2. PGE2 induces COX-2 and mPGES-1 synthesis in RAW 264.7 cells. A) Dose-
response effect of PGE2 on COX-2 and mPGES-1 mRNA expression. RAW 264.7 cells were 
stimulated with different doses of PGE2 (0.1 to 10 µM) for 24 h. B) Analysis of COX-2 and 
mPGES-1 protein levels by Western blot in extracts from RAW 264.7 cells treated with 
increasing doses of PGE2. β-Actin protein levels were determined as a control of loading. C) 
Time course mRNA induction of COX-2 and mPGES-1 after PGE2 treatment. RAW 264.7 
cells were treated with PGE2 (5 µM) for the times indicated (hours). D) PGE2 cooperates with 
LPS to induce COX-2 and mPGES-1 expression in macrophages. RAW 264.7 cells were 
treated with LPS (1 µg/ml) or LPS + PGE2 (5 µM) for different times. COX-2 and mPGES-1 
mRNA levels were analyzed by real time RT-PCR and normalized to the expression of 18S 
rRNA. Results are shown as the mean of fold induction over the control group ± SD of at least 
two independent experiments performed in triplicate (*p<0.05). 
 
Figure 3. Involvement of EP2 receptor on the transcriptional activation of COX-2 and 
mPGES-1. A) (left panel) Expression of EP receptors EP1, EP2, EP3 and EP4 in 
unstimulated RAW 264.7 macrophages. An aliquot of the amplified DNA was separated on 
an agarose gel and stained with ethidium bromide for qualitative comparison. The average Ct 
for each gene obtained by real time RT-PCR in basal conditions is indicated. β-actin mRNA 
levels are shown as a control of loading. (right) mRNA levels of EP receptors was analyzed 
by quantitative real time RT-PCR in RAW 264.7 cells stimulated with PGE2 (5 µM) or LPS 
(1 µg/ml) for the time indicated (hours). B) Analysis by real time RT-PCR of COX-2 and 
mPGES-1 expression in response to the EP2 agonist CAY10399 (1 µM) or the EP4 agonist 
PGE1OH (1 µM). C) Cells were treated with PGE2 (5 µM) in the presence or absence of EP2 
antagonist AH6809 (1-5 µM) and COX-2 and mPGES-1 mRNA levels were analyzed by real 
time RT-PCR. Relative quantification of mRNA levels was determined using endogenous 
expression of rRNA 18S and is shown as fold induction ± SD. D) EP2 mediates PGE2-
dependent transcriptional activation of COX-2 and mPGES-1 promoters. RAW 264.7 cells 
were transfected with PGHS-2 medium (COX-2-LUC) or mPGES-1-895 (mPGES-1-Luc) 
reporter plasmids along with empty vector (pcDNA3), or an expression vector for EP2. 
Transfected cells were stimulated with PGE2 (5 µM), and transcriptional activation of COX-2 
and mPGES-1 promoters was assayed. The means of replicate determinations of at least three 
independent assays expressed as fold induction ± SD are shown. (*p<0.05; **p<0.01). 
 
 18 
Figure 4. dbcAMP increases COX-2 and mPGES-1 expression and PGE2 production in 
RAW 264.7 cells. A) COX-2 and mPGES-1 mRNA levels from RAW 264.7 cells stimulated 
with dbcAMP (100 µM) at indicated times were determined by real time RT-PCR. Results are 
shown as the mean of fold induction ± SD of two independent experiments perfomed in 
triplicate. B) Western blot analysis of COX-2 and mPGES-1 protein expression in response to 
dbcAMP (100 µM) at different times of treatment (hours). C) PGE2 production by RAW 
264.7 cells after stimulation with dbcAMP during different times. The results shown are the 
mean ± SD of replicate determinations of three independent assays (*p<0.01; **p<0.05). 
 
Figure 5. dbcAMP cooperates with LPS in the induction of COX-2 and mPGES-1 
expression. A) Analysis of COX-2 and mPGES-1 expression in RAW 264.7 cells after 
stimulation with LPS (1 µg/ml) or LPS + dbcAMP (100 µM) for different times (hours). 
mRNA levels were analyzed by real time RT-PCR. A representative of three independent 
experiments is shown. B) PGE2 production in supernatants of RAW 264.7 cells treated with 
LPS or LPS + dbcAMP for different times. C) LPS and dbcAMP induce transcriptional 
activation of COX-2 and mPGES-1 promoter. Luciferase activity of COX-2 and mPGES-1 
luciferase construct containing the proximal promoter regions of these genes in transfected 
cells treated with dbcAMP, LPS or LPS + dbcAMP for 24 h. Results from three independent 
experiment are shown as Fold induction (observed experimental RLUs/basal RLUs in absence 
of any stimuli) ± SD. Paired t student tests indicate a significant difference between LPS and 
LPS + dbcAMP groups (**p<0.01; *p<0.05). 
 
Figure 6. Involvement of PKA on COX-2 and mPGES-1 expression. A) COX-2 and 
mPGES-1 mRNA levels were analyzed by quantitative real time RT-PCR in cells treated with 
Forskolin (Forsk) (10 µM) or PGE2 (5 µM) for 24 h in the presence of PKA inhibitor H89 (10 
µM). Data from two independent experiments performed by triplicate were normalized to the 
levels of the endogenous control 18 S rRNA and are shown as Fold induction ± SD. B) 
Luciferase activity of COX-2 Luc and mPGES-1 Luc constructs were analyzed in RAW 264.7 
cells transiently transfected with the EP2 receptor. Cells were pre-treated with H89 1 h prior 
PGE2 stimulation for 18 h. Luciferase activity is shown as Fold induction ± SD. A 
representative of three independent experiments performed by triplicate is shown. C) Activity 
of COX-2 Luc and mPGES-1 Luc constructs in RAW 264.7 cells transiently transfected with 
an expression vector for the catalytic subunit of PKA and treated or not with LPS for 18 h. 
Luciferase activity is shown as Fold induction ± SD. Statistical difference over the control 
group is shown (***p<0.005; **p<0.01; *p<0.05). D) Analysis of PGE2
Figure 7. PGE
 production in 
supernatants of RAW 264.7 cells pretreated with PKA inhibitors H89 or KT5720 before 
stimulation with LPS + dbcAMP for 24 h. Results are means ± SD from three experiments. 
Paired t student tests indicate a significant difference between stimulated and H89 or KT5720 
treated groups (***p<0.005; **p<0.01; *p<0.05). 
 
2 induces CRE-mediated transcriptional activation. A) RAW 264.7 
macrophages were incubated in the absence or presence of PGE2 (5 µM) for the indicated 
period of time (minutes). Protein extracts were separated by SDS-PAGE and levels of 
phosphorylated (P) and total CREB were detected by immunoblotting with specific 
antibodies. Relative quantification of CREB phosphorylation is shown in the lower panel. B) 
RAW 264.7 cells were transiently transfected with a CRE -dependent luciferase reporter 
plasmid (CRE-Luc) and treated with PGE2 (5 µM), Forskolin (10 µM) or dbcAMP (100 µM) 
for 18 h. Data are the mean ± SD of replicate determinations expressed as fold induction over 
the RLUs of unstimulated controls (Cont) Results are representatives of at least two 
independent experiments. C) RAW 264.7 cells were transfected with CRE-LUC reporter 
plasmid along with empty vector (pcDNA3) or an expression vector for EP2 receptor. 
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Transfected cells were stimulated with PGE2 and CRE-dependent transcriptional activation 
was assayed. The means of replicate determinations expressed as fold induction ± SD are 
shown. Results are representative of at least three independent assays. (*p<0.05; ** p<0.005). 
 
Figure 8. PGE2 –mediated activation and CREB binding in COX-2 and mPGES-1 
promoter regions. RAW 264.7 cells were transfected with different deletions of COX-2 (A) 
or mPGES-1 (C) promoter constructs (described in Material and Methods) along with EP2 
receptor expression vector. Cis-acting consensus sequences are denoted by boxes. The extent 
of the 5´ truncations are shown with numbers indicating their length relative to the 
transcription start site. After transfection, cells were treated with PGE2 (5 µM) for 18 h and 
assayed for luciferase activity. Data are shown as means of fold induction (observed 
experimental RLUs in response to LPS/basal RLUs in absence of any stimuli) ± SD of three 
different experiments. Analysis of the specific binding of CREB to COX-2 (B) and mPGES-1 
(D) promoter regions in RAW 264.7 macrophages by ChIP assays. CREB transcription factor 
was immunoprecipitated from cells stimulated with PGE2 (5µM) for the times indicated 
(minutes). Immunoprecipitated DNA was amplified with specifics primers for the COX-2 or 
the mPGES-1 proximal promoter regions. As a control, PCR was performed on chromatin 
fragments isolated before immunoprecipitation (input). Immunoprecipitation with a normal 
rabbit serum (NRS) was carried out in parallel as negative control. The results shown are a 
representative experiment of the three experiment performed. 
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